Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Summary of findings ‐ Pfaffia paniculata vs placebo

Quality of life measures · children with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Summary of findings ‐ Pfaffia paniculata vs placebo

Number of sickle cells, peripheral erythroblasts and reticulocytes · children with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Summary of findings ‐ Niprisan® vs placebo

Frequency of hospital admissions from severe complications of SCD · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
70 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Any adverse events including hepatic and renal toxicity · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
80 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Frequency of blood transfusion · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Niprisan® vs placebo

Change in haemoglobin level from baseline · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
52 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Quality of life measures: self reported health, absence from work or school · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
70 participants
Very low

Summary of findings ‐ Ciklavit® vs placebo

Frequency, severity or duration of painful crises · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low

Summary of findings ‐ Ciklavit® vs placebo

Frequency of severe complications of SCD · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Insulin vs placebo

HbA1c (%) · adults with CFRD

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Summary of findings: repaglinide vs placebo

Hypoglycemia: number of episodes · adults with CFRD

It is very uncertain whether summary of findings: repaglinide changes hypoglycemia: number of episodes compared with placebo (very low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
RR 12.52 [0.74, 211.2]
1 study · 51 participants
Very low

Summary of findings: repaglinide vs insulin

HbA1c (glycated haemoglobin), change · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in hbA1c (%) change from baseline compared with insulin (high certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.3
1 study · 67 participants
High

Summary of findings: repaglinide vs insulin

FEV1 (% predicted): mean change from baseline · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in FEV1 % predicted change from baseline compared with insulin (moderate certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Summary of findings: repaglinide vs insulin

FVC (% predicted) Change from baseline · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Summary of findings: repaglinide vs insulin

Change in BMI · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in BMI (kg/m²) change from baseline compared with insulin (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.24
1 study · 45 participants
Low

Summary of findings: repaglinide vs insulin

Hypoglycemia: number of episodes · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in hypoglycemia number of episodes compared with insulin (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
RR 1.38 [0.48, 4.01]
2 studies · 56 participants
Low

Summary of findings: NPH insulin vs insulin glargine

HbA1c (%) · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

FEV1 % predicted · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

FVC · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: NPH insulin vs insulin glargine

Body‐mass index (BMI) · adults with CFRD and fasting hyperglycemia

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found